Danaher Corporation (NYSE: DHR) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 36.39 | EPS (ttm) | 5.63 | Insider Own | 1.03% | Shs Outstand | 702.99M | Perf Week | -1.01% |
| Market Cap | 144.01B | Forward P/E | 22.06 | EPS next Y | 9.29 | Insider Trans | -0.83% | Shs Float | 625.84M | Perf Month | -2.16% |
| Enterprise Value | 166.22B | PEG | 3.61 | EPS next Q | 1.96 | Inst Own | 77.39% | Short Float | 1.40% | Perf Quarter | 8.73% |
| Income | 4.00B | P/S | 5.74 | EPS this Y | 51.04% | Inst Trans | 0.00% | Short Ratio | 1.79 | Perf Half Y | 4.93% |
| Sales | 25.11B | P/B | 2.74 | EPS next Y | 9.21% | ROA | 4.33% | Short Interest | 8.78M | Perf YTD | -10.51% |
| Book/sh | 74.81 | P/C | 33.12 | EPS next 5Y | 10.07% | ROE | 7.66% | 52W High | 242.80 -15.63% | Perf Year | 3.13% |
| Cash/sh | 6.18 | P/FCF | 26.71 | EPS past 3/5Y | -19.44% 0.61% | ROIC | 5.03% | 52W Low | 160.93 27.29% | Perf 3Y | -12.99% |
| Dividend Est. | 1.60 (0.78%) | EV/EBITDA | 23.24 | Sales past 3/5Y | -2.67% 1.97% | Gross Margin | 58.51% | Volatility | 2.60% 2.59% | Perf 5Y | -28.71% |
| Dividend TTM | 1.44 (0.70%) | EV/Sales | 6.62 | EPS Y/Y TTM | 6.43% | Oper. Margin | 20.42% | ATR (14) | 6.10 | Perf 10Y | 182.40% |
| Dividend Ex-Date | Jun 26, 2026 | Quick Ratio | 1.25 | Sales Y/Y TTM | 5.16% | Profit Margin | 15.95% | RSI (14) | 46.96 | Recom | 2.30 |
| Dividend Gr. 3/5Y | 13.02% 14.93% | Current Ratio | 1.65 | EPS Q/Q | 7.78% | SMA20 | -2.40% | Beta | 0.77 | Target Price | 223.77 |
| Payout | 24.08% | Debt/Eq | 0.35 | Sales Q/Q | 5.54% | SMA50 | 1.39% | Rel Volume | 0.60 | Prev Close | 205.23 |
| Employees | 59,000 | LT Debt/Eq | 0.35 | Earnings | Oct 20 | SMA200 | 1.09% | Avg Volume | 4.59M | Price | 204.85 |
| IPO Date | Dec 29, 1978 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 4.83% 2.35% | Net Debt/EBITDA | 3.11 | Volume | 2,773,126 | Change | -0.19% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | UBS | Buy | $240 → $250 |
| Jul-22-26 | Reiterated | Deutsche Bank | Buy | $250 → $240 |
| Jul-22-26 | Reiterated | Stifel Nicolaus | Hold | $260 → $220 |
| Jul-22-26 | Reiterated | Wells Fargo | Equal Weight | $240 → $195 |
| Jul-22-26 | Reiterated | RBC Capital | Outperform | $200 → $215 |
| Jul-22-26 | Reiterated | Guggenheim | Buy | $275 → $200 |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $254 → $230 |
| Jun-11-26 | Reiterated | Piper Sandler | Neutral | $200 |
| Jun-03-26 | Reiterated | HSBC | Buy | $280 → $230 |
| May-27-26 | Downgrade | Citigroup | Buy → Neutral |
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians' offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 25,107 | 24,568 | 23,875 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 10,416 | 9,598 | 9,669 | — | — | — | — | — | — | |
| Gross Profit | 14,691 | 14,970 | 14,206 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 7,949 | 8,235 | 7,438 | — | — | — | — | — | — | |
| Research and Development | 1,615 | 1,598 | 1,584 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | 5,127 | 5,137 | 5,184 | — | — | — | — | — | — | |
| Interest Expense | 78 | 265 | 278 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -287 | -639 | -260 | — | — | — | — | — | — | |
| Net Income Before Taxes | 4,762 | 4,233 | 4,646 | — | — | — | — | — | — | |
| Income Taxes | 758 | 619 | 747 | — | — | — | — | — | — | |
| Consolidated Net Income | 4,004 | 3,614 | 3,899 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 4,004 | 3,614 | 3,899 | — | — | — | — | — | — | |
| Net Income | 4,004 | 3,614 | 3,899 | — | — | — | — | — | — | |
| EPS (Recurring) | 5.65 | 5.07 | 5.33 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 5.65 | 5.07 | 5.33 | — | — | — | — | — | — | |
| EPS (Diluted) | 5.63 | 5.04 | 5.29 | — | — | — | — | — | — | |
| EBITDA | 7,151 | 6,945 | 7,276 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 36.39 | 45.42 | 43.39 | — | — | — | — | — | — | |
| Price To Sales Ratio | 5.75 | 6.59 | 7.03 | — | — | — | — | — | — | |
| Gross Margin | 58.51 | 60.93 | 59.50 | — | — | — | — | — | — | |
| Operating Margin | 20.42 | 20.91 | 21.71 | — | — | — | — | — | — | |
| Net Margin | 15.95 | 14.71 | 16.33 | — | — | — | — | — | — | |
| Shares Outstanding | 705 | 707 | 731 | — | — | — | — | — | — | |
| Market Capitalization | 144,419 | 161,846 | 167,801 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Blair Rainer | President & CEO | Aug 21 '26 | Sale | 218.63 | 58,255 | 12,736,095 | 0 | Aug 24 |
| FILLER LINDA | Director | Jul 15 '26 | Option Exercise | 71.88 | 3,298 | 237,060 | 28,010 | Jul 16 |
| Zerhouni Elias A. | Director | Jul 15 '26 | Option Exercise | 71.88 | 3,298 | 237,060 | 46,484 | Jul 16 |
| SPOON ALAN G | Director | May 01 '26 | Option Exercise | 71.88 | 3,298 | 237,060 | 125,452 | May 04 |
| SPOON ALAN G | Director | May 01 '26 | Sale | 174.67 | 1,358 | 237,207 | 124,094 | May 04 |
| Milosevich Gregory M | Executive Vice President | Feb 19 '26 | Option Exercise | 58.59 | 1,320 | 77,339 | 6,419 | Feb 20 |
| Milosevich Gregory M | Executive Vice President | Feb 19 '26 | Sale | 208.01 | 1,320 | 274,575 | 5,099 | Feb 20 |
| RALES MITCHELL P | Chairman of Exec. Committee | Nov 25 '25 | Sale | 230.38 | 40,625 | 9,359,067 | 850,000 | Nov 26 |
| List Teri | Director | Nov 18 '25 | Option Exercise | 71.88 | 3,298 | 237,060 | 24,060 | Nov 19 |
| List Teri | Director | Nov 18 '25 | Sale | 226.50 | 3,298 | 746,997 | 20,762 | Nov 19 |
| RALES MITCHELL P | Chairman of Exec. Committee | Nov 12 '25 | Sale | 218.69 | 437,000 | 95,566,166 | 553,228 | Nov 13 |
| Ellis Brian W | Senior Vice President - GC | Nov 12 '25 | Option Exercise | 58.59 | 21,776 | 1,275,856 | 29,220 | Nov 13 |
| Ellis Brian W | Senior Vice President - GC | Nov 12 '25 | Sale | 219.23 | 21,776 | 4,773,863 | 14,553 | Nov 13 |
| McGrew Matthew | EVP & Chief Financial Officer | Nov 11 '25 | Option Exercise | 62.85 | 16,172 | 1,016,410 | 36,234 | Nov 13 |
| McGrew Matthew | EVP & Chief Financial Officer | Nov 11 '25 | Sale | 214.62 | 16,172 | 3,470,831 | 20,062 | Nov 13 |